UK-based start-up Kheiron Medical Technologies has obtained the European CE-Mark for its new artificial intelligence (AI)-based breast cancer screening software as a second reader of mammographic images.

The software leverages deep learning that uses artificial neural networks and performance computing to precisely analyse complex medical images.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
“The tool is anticipated to reduce the screening workload of clinical staff in all types of settings, and offer a new option for the NHS to cater to the ongoing radiology workforce shortage.”

Kheiron said that the algorithm will facilitate efficient and accurate breast cancer detection at early stages. It is also expected to decrease the unnecessary invasive biopsies and radiation.

The company expects the breast cancer screening software to be launched on the country’s National Health Service (NHS) and European healthcare systems.

The tool is anticipated to reduce the screening workload of clinical staff in all types of settings, and offer a new option for the NHS to cater to the ongoing radiology workforce shortage.

Kheiron Medical Technologies chief medical officer Christopher Austin said: “With UK radiology workforce shortages in the spotlight, regulatory approval could actually position the UK and Europe as the world’s earliest adopters of AI at scale.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“European national breast screening programmes can now take the lead and demonstrate how to leverage high quality, proven, and safe machine learning technologies to run screening programmes better, smarter and more cost-effectively for millions of women.”

In an independent multi-centre clinical study, the new breast cancer screening software demonstrated better accuracy compared to single radiologist reporting.

The company is additionally conducting multi-phase clinical evaluations across the UK, Europe and the US to further evaluate and improve the performance of the AI-based software.